The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27190600 |
48 |
Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. |
Merck Research Laboratories |
| 27106708 |
130 |
The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors. |
Merck Research Laboratories |
| 2016726 |
5 |
New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
Katholieke Universiteit Leuven |
| 2016725 |
34 |
New derivatives of kanamycin B obtained by modifications and substitutions in position 6''. 2. In vitro and computer-aided toxicological evaluation with respect to interactions with phosphatidylinositol. |
Universit£ |
| 32527554 |
11 |
A cell-based fluorescent assay for FAP inhibitor discovery. |
Peking University First Hospital |
| 27670099 |
43 |
Scaffold-hopping from xanthines to tricyclic guanines: A case study of dipeptidyl peptidase 4 (DPP4) inhibitors. |
Merck Research Laboratories |
| 31393718 |
26 |
Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein ?. |
Mcgill University |
Search and Browse
